Suresnes / Paris / Vancouver / Indianapolis / Illkirch / Marseille / St. Louis / Newcastle / Cergy Pontoise / Marseilles / Dijon / Chatillon / Plaisir / Mannheim / Miami / /
Company
MiaPaCa / Life Technologies Inc. / Roche Diagnostics GmbH / Millipore / Qiagen / Brain Power Inc. / Lilly Pharmaceutical Company / Mauk AG / Epitomic Inc. / IgG / Dr Gleave / ISIS Pharmaceuticals / OncoGenex Technologies / Beckman Coulter / Becton Dickinson / Santa Cruz Biotechnology Inc. / Fuqua SA. / HP / Harlan Sprague Dawley Inc. / Beckman Inc. / Macmillan Publishers Limited / /
Country
France / Canada / United Kingdom / Germany / Oesterreich / United States / / /
Prostate Centre / Ottawa University / Interest The University of British Columbia / The Prostate Centre / Vancouver General Hospital / Timone Hospital / South Alabama University / University of South Alabama / National Cancer Institute of Canada Clinical Trials Group / /
pancreatic tumors / several tumor / pancreas cancer / du cancer / less aggressive tumors / each tumor / prostate cancer / UD ductal adenocarcinoma / hormone-refractory prostate cancer / adenocarcinoma / tumor / cancer / tumors / different cancers / sur le Cancer / advanced tumors / tumor glands / pancreas adenocarcinomas / doxorubicin-treated breast cancer / Lentiviral Infection / pancreatic ductal adenocarcinoma / Mean tumor / chemoresistant cancers / endocrine pancreas tumors / intraductal papillary mucinous neoplasms / human pancreas cancer TMA / human pancreatic cancer / metastasis / advanced pancreatic cancer / human pancreas cancer tumors / vivo tumor / moderately differentiated tumors / gastric adenocarcinoma / J Cancer / bladder carcinoma / human ovarian cancer / pancreatic cancer / lung cancers / gemcitabine-resistant pancreatic cancer / breast cancers / Disease / human bladder cancer / early and advanced breast cancer / average tumor / Cancer Pancreatic cancer / metastatic tumors / metastatic pancreatic cancer / pancreatic cancer V Baylot1 / intensively reactive tumor / la ligue contre le cancer / weakly positive cancer / pancreas carcinoma / /
MedicalTreatment
cancer therapy / combination chemotherapy / chemotherapy / /
OperatingSystem
ISIS / /
Organization
l’Institut National / National Cancer Institute of Canada Clinical Trials Group / Timone Hospital / University of South Alabama / UD PC / Ottawa University / l’institut / Faculty of Medicine / Hsp27 / South Alabama University / Hsp27 association / Pathology Department / Prostate Centre / Vancouver General Hospital / Hsp27eIF4E association / 2Aix-Marseille Universite / University of British Columbia / /
Person
Rocchi / Lavaut / Virginia Yago / Van Laethem / Ann Oncol / Gleave / William Gerthoffer / Nova Castra / Nelson C et al. Increased / / /
Position
King / representative / *Corresponding author / Fisher / /
Product
androgen / paclitaxel / Gemzar / National Cancer Institute / OGX-427 / Hsp27 / /
ProvinceOrState
British Columbia / Ontario / Delaware / /
PublishedMedium
la Recherche / /
RadioStation
Egloff AM / /
Region
South Alabama / /
Technology
Proteomics / siRNA / apoptosis / Cell Signaling technology / DNA Chip / gene expression / chemotherapy / treating cancer / recombination / av / antibodies / biotechnology / laser / avi / /
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer